Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Lunaphore and Acd Revolutionize Spatial Biology Research With the Launch of the First Fully Automated, Same-Section, Hyperplex Multiomics Application

Bio-Techne Corporation (NASDAQ: TECH) today announced that its spatial biology brands, Lunaphore and Advanced Cell Diagnostics (ACD), will launch the first fully automated spatial multiomics workflow with same-section hyperplex detection of RNA and protein biomarkers.

From Bio-Techne 25 Jan 2024

Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine

Researchers analyzed the toxicity concerns and advancements in mRNA therapeutics, focusing on their cellular toxicity, reactogenicity, and distribution, and discussed the challenges and benefits of mRNA research.

24 Jan 2024

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

24 Jan 2024

3D-printed liver model paves way for new MASH treatments

Metabolic dysfunction- associated steatohepatitis, or MASH, is an inflammatory, liver-scarring disease that has reached epidemic proportions, with an estimated 1.5% to 6.5% of U.S. adults afflicted by the condition, and roughly 24% of adults having nonalcoholic fatty liver disease (NAFLD).

23 Jan 2024

C-Path's TRxA launches 2024 grants to boost next-gen therapeutics

Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe.

23 Jan 2024

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

...

From CN-Bio 23 Jan 2024

Moffitt researchers develop novel reagent for efficient synthesis of sulfur-containing drug candidates

During the past decade, there has been significant development of new sulfur containing compounds that are used in various industries, including pharmaceuticals and agricultural products.

22 Jan 2024

WFIRM leads $40M regenerative medicine initiative for the wounded and beyond

The Wake Forest Institute for Regenerative Medicine, part of Wake Forest University School of Medicine, has been selected to lead the Armed Forces Institute of Regenerative Medicine (AFIRM) Consortium.

22 Jan 2024

Discovery of toxic and protective short RNAs associated with Alzheimer's disease and superior memory capacity

Researchers explored how Death Induced by Survival gene Elimination through the analysis of RNA-induced silencing complex-bound short RNAs in Alzheimer's disease models influences neuronal survival and correlates with neurotoxicity in AD.

22 Jan 2024

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Clinical stage generative artificial intelligence (AI)-driven biotechnology company InSilico Medicine ("InSilico"), today announced that the Journal of Medicinal Chemistry, an ACS Publications journal focusing on critical studies about molecular structure and biological activity, has published the company's discovery of a novel PHD inhibitor for the treatment of anemia.

19 Jan 2024

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

19 Jan 2024

Short strands of toxic RNAs contribute to brain cell death and DNA damage in Alzheimer's

Alzheimer's disease, which is expected to have affected about 6.7 million patients in the U.S. in 2023, results in a substantial loss of brain cells.

18 Jan 2024

Conscience's open science competition yields hits for new Parkinson's drugs

As part of its pioneering approach to drug discovery, the Canadian nonprofit Conscience announced today that its first open science competition has resulted in the identification of seven promising molecules, or "hits," that show potential for new, more effective drugs for familial Parkinson's disease.

16 Jan 2024

Pioneering Genomic Progress: An Interview with Rami Mehio, Illumina's Software and Informatics Expert

In this interview, Rami Mehio, head of software and informatics at Illumina, shares his experiences and contributions to major genomic projects like the UK Biobank's whole genome sequencing. He discusses the challenges and innovations in genomic data analysis, highlighting Illumina's role in advancing genetic research and precision medicine.

From Illumina, Inc. 15 Jan 2024

New analysis of cancer cells identifies 370 targets for smarter, personalized treatments

A new, systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types, including breast, lung and ovarian cancers.

13 Jan 2024

3D nanomatrix vascular sheet model for high-throughput atherosclerosis drug testing

A groundbreaking 3D, three-layer nanomatrix vascular sheet that possesses multiple features of atherosclerosis has been applied for developing a high-throughput functional assay of drug candidates to treat this disease, University of Alabama at Birmingham researchers report in the journal Biomaterials.

12 Jan 2024

When mass spectrometry redefines the pharma industry

In this new episode of omg OMx, Kate Stumpo speaks to Bruker's Mike Greig about the incredible potential of mass spectrometry in pharma.

From Bruker Life Sciences Mass Spectrometry 12 Jan 2024

New molecule targets key protein in autoimmune diseases

Scientists from Scripps Research have developed a small molecule that blocks the activity of a protein linked to autoimmune diseases, including systemic lupus erythematosus (SLE) and Crohn's disease.

11 Jan 2024

New developments at Evosep to make clinical proteomics 100x more robust and 10x faster

J.P. Morgan Healthcare Conference – (January 8th, 2024) Evosep, a leading provider of sample preparation solutions for mass spectrometry-based proteomics, today announced a co-marketing agreement with Thermo Fisher Scientific, a world leader in serving science.

From Thermo Fisher Scientific Inc. 10 Jan 2024

SickKids scientists untangle cellular waste buildup in Zellweger Spectrum Disorder

For the first time, a research team at The Hospital for Sick Children (SickKids) has uncovered a way to potentially reduce the amount of toxic cellular waste accumulating in patients with Zellweger Spectrum Disorder (ZSD).

9 Jan 2024

Drug Discovery News and Research

Further Reading

Lunaphore and Acd Revolutionize Spatial Biology Research With the Launch of the First Fully Automated, Same-Section, Hyperplex Multiomics Application

Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

3D-printed liver model paves way for new MASH treatments

C-Path's TRxA launches 2024 grants to boost next-gen therapeutics

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

Moffitt researchers develop novel reagent for efficient synthesis of sulfur-containing drug candidates

WFIRM leads $40M regenerative medicine initiative for the wounded and beyond

Discovery of toxic and protective short RNAs associated with Alzheimer's disease and superior memory capacity

AI scores breakthrough in anemia treatment with novel PHD inhibitor

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Short strands of toxic RNAs contribute to brain cell death and DNA damage in Alzheimer's

Conscience's open science competition yields hits for new Parkinson's drugs

Pioneering Genomic Progress: An Interview with Rami Mehio, Illumina's Software and Informatics Expert

New analysis of cancer cells identifies 370 targets for smarter, personalized treatments

3D nanomatrix vascular sheet model for high-throughput atherosclerosis drug testing

When mass spectrometry redefines the pharma industry

New molecule targets key protein in autoimmune diseases

New developments at Evosep to make clinical proteomics 100x more robust and 10x faster

SickKids scientists untangle cellular waste buildup in Zellweger Spectrum Disorder

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News